8th February 2018



Notice of Preliminary Results


Chippenham, UK, 8 February 2018: Vectura Group plc (LSE: VEC) ("Vectura" or the "Group"), an industry-leading device and formulation business for inhaled airways products, plans to announce its Preliminary Results for the 12 months ended 31 December 2017 on Wednesday 21 March 2018.

James Ward-Lilley, Chief Executive Officer, and Andrew Derodra, Chief Financial Officer, will host a briefing for analysts at 9.30am on the morning of the results at the offices of Numis Securities Ltd., 10 Paternoster Square, London, EC4M 7LT. 

A live webcast of the meeting, with the presentation slides, will be available on Vectura’s website: http://www.vectura.com/investors/presentations-webcasts/.  

- ENDS -


For more information, please contact:


Vectura Group plc

+44 (0)1249 667700

Elizabeth Knowles – Director Investor Relations and Analysis

David Ginivan – VP Corporate Communications




Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / Chris Welsh / Jessica Hodgson




About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With our extensive range of device and formulation technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.

Vectura has eight inhaled, three non-inhaled and ten oral products marketed by partners with growing global royalty streams.  The Group has a diverse portfolio of drugs in clinical development, including a number of novel and generic programmes which are partnered with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork along with two wholly owned nebulised development programmes.

For further information, please visit Vectura's website at www.vectura.com.

Back to previous page